Spyre Therapeutics (SYRE) Total Liabilities (2015 - 2026)
Spyre Therapeutics' (SYRE) quarterly Total Liabilities came in at $93.1 million in Q1 2026, up 6.85% YoY from $87.2 million in Q1 2025, and up 48.92% on a QoQ basis from $62.5 million in Q4 2025.
Spyre Therapeutics (SYRE) Total Liabilities (2015 - 2026) Analysis & Trends
Spyre Therapeutics (SYRE) has 12 years of Total Liabilities data on file, last reported at $93.1 million in Q1 2026.
- Quarterly Total Liabilities rose 6.85% year-over-year to $93.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $93.1 million (up 6.85% YoY) and the FY2025 annual result came in at $62.5 million, down 31.03% from the prior year.
- Total Liabilities climbed to $93.1 million in Q1 2026, from $62.5 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $253.6 million in Q2 2023 to a low of $18.8 million in Q1 2023.
- A 5-year average of $70.8 million and a median of $65.6 million in 2023 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2023 — Total Liabilities jumped 1024.5% — and 2024, when it plunged 75.68%.
- Tracing SYRE's Total Liabilities over 5 years: stood at $20.8 million in 2022, then surged by 251.69% to $73.3 million in 2023, then grew by 23.73% to $90.7 million in 2024, then slumped by 31.03% to $62.5 million in 2025, then soared by 48.92% to $93.1 million in 2026.
- The last three Total Liabilities figures came in at $93.1 million (Q1 2026), $62.5 million (Q4 2025), and $49.5 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | Spyre Therapeutics | 9.13 Bn | 9.13 Bn | - | 71.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 71.86 Mn |
| Mar 31, 2026 | 93.14 Mn |
| Dec 31, 2025 | 62.55 Mn |
| Sep 30, 2025 | 49.50 Mn |
| Jun 30, 2025 | 83.06 Mn |
| Mar 31, 2025 | 87.17 Mn |
| Dec 31, 2024 | 90.68 Mn |
| Sep 30, 2024 | 93.70 Mn |
| Jun 30, 2024 | 61.68 Mn |
| Mar 31, 2024 | 81.93 Mn |
| Dec 31, 2023 | 73.29 Mn |
| Sep 30, 2023 | 65.56 Mn |
| Jun 30, 2023 | 253.58 Mn |
| Mar 31, 2023 | 18.80 Mn |
| Dec 31, 2022 | 20.84 Mn |
| Sep 30, 2022 | 24.01 Mn |
| Jun 30, 2022 | 22.55 Mn |
| Mar 31, 2022 | 21.51 Mn |
| Dec 31, 2021 | 25.99 Mn |
| Sep 30, 2021 | 26.98 Mn |